Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 save search
iSpecimen Expands Support of COVID-19 Research with Availability of Sequenced Specimens to Detect Variants
Published: 2022-01-13 (Crawled : 14:00) - biospace.com/
ISPC | $0.2915 -30.76% -44.43% 2.8M
|
Professional, Scientific, and T...
|
| O: 7.99%
H: 0.78%
C: -9.74%
covid-19 research covid
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-19 (Crawled : 17:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting respiratory review authorization
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk
Published: 2022-09-19 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting review authorization
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-11-10 (Crawled : 02:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.09%
H: 0.48%
C: 0.4%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -58.83%
H: 25.89%
C: 12.78%
covid-19 fda risk sabizabulin meeting respiratory authorization update
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Veru, Immunome Tout Positive Data for COVID-19 Therapeutics
Published: 2022-07-06 (Crawled : 17:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
IMNM | $15.5 -9.78% -10.84% 2.1M
|
Health Technology
|
| O: 2.63%
H: 12.54%
C: 9.69%
covid-19 therapeutics positive
European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries
Published: 2022-07-27 (Crawled : 15:20) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.57%
C: -0.01%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.81%
H: 3.05%
C: 1.2%
covid-19 treatment sabizabulin review initiated
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-08-09 (Crawled : 15:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.86%
H: 0.53%
C: -0.68%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.5%
H: 2.25%
C: -4.17%
covid-19 treatment risk sabizabulin respiratory presentation study
Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories
Published: 2022-08-11 (Crawled : 12:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.82%
H: 26.51%
C: 12.59%
covid-19 treatment sabizabulin
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Published: 2022-07-25 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: 0.85%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 3.41%
H: 0.07%
C: -8.65%
covid-19 treatment sabizabulin application review authorization
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
Published: 2022-08-22 (Crawled : 13:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.15%
H: 1.08%
C: 0.25%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 5.44%
H: 3.53%
C: -7.93%
covid-19 treatment sabizabulin granted
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
Published: 2022-08-19 (Crawled : 13:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.25%
H: 2.6%
C: 1.66%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -3.19%
H: 7.78%
C: -3.37%
covid-19 disease international
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-07 (Crawled : 18:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.64%
H: 1.18%
C: 0.92%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 9.6%
H: 3.38%
C: -28.02%
covid-19 fda risk sabizabulin meeting respiratory review authorization
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Published: 2022-09-14 (Crawled : 12:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 1.89%
H: 3.06%
C: 0.64%
covid-19 risk sabizabulin pharma services commercial respiratory agreement
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.47%
H: 5.06%
C: -4.11%
covid-19 covid report phase 3 sabizabulin
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
Published: 2023-04-04 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.72%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 7.89%
H: 1.63%
C: -9.76%
covid-19 sabizabulin respiratory update preclinical program results
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published: 2023-05-04 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.06%
H: 0.29%
C: -0.7%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.0%
covid-19 fda sabizabulin treatment risk trial agreement
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.89%
H: 27.06%
C: 24.67%
covid-19 treatment sabizabulin presentation phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.